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and APP co-localized in presynaptic dystrophies, imply-
ing increased BACE1 processing of APP in peri-plaque 
regions. In primary cortical neuron cultures, treatment with 
the lysosomal protease inhibitor leupeptin caused BACE1 
levels to increase; however, exposure of neurons to the 
autophagy inducer trehalose did not reduce BACE1 levels. 
This suggests that BACE1 is degraded by lysosomes but 
not by autophagy. Our results imply that BACE1 elevation 
in AD could be linked to decreased lysosomal degradation 
of BACE1 within dystrophic presynaptic terminals. Ele-
vated BACE1 and APP levels in plaque-associated presyn-
aptic dystrophies could increase local peri-plaque Aβ gen-
eration and accelerate amyloid plaque growth in AD.
Keywords Alzheimer’s disease · BACE1 · β-Secretase · 
Aβ · Amyloid plaque · Dystrophic neurite · Lysosome · 
Autophagy
Introduction
Alzheimer’s disease (AD) is characterized by the pres-
ence of neurofibrillary tangles and cerebral amyloid plaques 
composed of the 40–42 amino acid β-amyloid peptide (Aβ; 
reviewed in Sisodia and Hyslop [98]). Much evidence impli-
cates Aβ in the pathogenesis of AD (reviewed in [102]). Aβ is 
generated from the sequential proteolysis of amyloid precur-
sor protein (APP) by the enzymes β-secretase and γ-secretase 
(reviewed in [21, 122]). β-Secretase initiates the cleavage of 
APP and has been identified as the transmembrane aspartic 
protease beta-site APP cleaving enzyme 1 (BACE1) [40, 64, 
96, 106, 118]. As the initiator enzyme of the amyloidogenic 
pathway, BACE1 is a prime therapeutic target for reducing 
cerebral Aβ levels, and several BACE1 inhibitor drug candi-
dates are currently in clinical trials for AD.
Abstract β-Site amyloid precursor protein (APP) cleav-
ing enzyme-1 (BACE1) is the β-secretase that initiates Aβ 
production in Alzheimer’s disease (AD). BACE1 levels 
are increased in AD, which could contribute to pathogen-
esis, yet the mechanism of BACE1 elevation is unclear. 
Furthermore, the normal function of BACE1 is poorly 
understood. We localized BACE1 in the brain at both the 
light and electron microscopic levels to gain insight into 
normal and pathophysiologic roles of BACE1 in health 
and AD, respectively. Our findings provide the first ultras-
tructural evidence that BACE1 localizes to vesicles (likely 
endosomes) in normal hippocampal mossy fiber termi-
nals of both non-transgenic and APP transgenic (5XFAD) 
mouse brains. In some instances, BACE1-positive vesicles 
were located near active zones, implying a function for 
BACE1 at the synapse. In addition, BACE1 accumulated 
in swollen dystrophic autophagosome-poor presynaptic 
terminals surrounding amyloid plaques in 5XFAD cortex 
and hippocampus. Importantly, accumulations of BACE1 
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Elucidating the physiological functions of BACE1 is 
essential for predicting potential mechanism-based tox-
icities associated with BACE1 inhibition as a therapeutic 
approach for AD. BACE1-null mice display complex neu-
rological phenotypes, including growth retardation [24], 
memory deficits [57, 77, 78], hypomyelination [37, 113], 
seizures [33, 39, 50], axon guidance defects [13, 32, 85], 
and schizophrenia-like behaviors [91]. These BACE1−/− 
phenotypes likely reflect the functions of a diverse array of 
BACE1 substrates that include Golgi-localized membrane-
bound α2,6-sialyltransferase [49], P-selectin glycoprotein 
ligand-1 [63], APP and the APP homolog proteins APLP1 
and APLP2 [25, 61, 79], low density lipoprotein receptor-
related protein [108], the voltage-gated sodium channel β2 
subunit (Navβ2) [46, 47, 114], neuregulin-1 (NRG1) [37, 
113], neuregulin-3 (NRG3) [36], and Close Homolog of L1 
(CHL1) [32, 55, 123], among others [55, 123]. Additional 
as yet unknown BACE1 substrates are likely to exist and 
their identification will provide further insight into the bio-
logical functions of BACE1.
Understanding the subcellular localization of BACE1 
may provide important clues as to the identities of key 
BACE1 substrates and the physiological functions of sub-
strate processing by BACE1, especially in neurons of the 
brain where therapeutic inhibition of BACE1 will be tar-
geted. Previously, using immunohistochemistry with a 
mono-specific anti-BACE1 antibody, we reported that 
BACE1 accumulates in swollen presynaptic neuronal 
structures that surround amyloid plaques in AD and APP 
transgenic brains [121]. In that and another study, we also 
observed that BACE1 levels in the normal mouse brain 
were highest in axon terminal fields, especially within pre-
synaptic terminals of the hippocampal mossy fiber pathway 
in CA3 [32, 121]. These results suggest that BACE1 has 
normal and aberrant presynaptic roles in non-demented and 
Alzheimer disease brains, respectively.
To further characterize the localization of BACE1 at both 
the light and electron microscopic levels and thereby infer 
potential normal and abnormal activities of BACE1 in the 
brain, we performed immunofluorescence confocal micros-
copy and immunogold electron microscopy (EM) of mossy 
fiber terminal regions in the hippocampal CA3 subregion in 
non-transgenic and APP transgenic (5XFAD) mouse brains. 
The high level of BACE1 in the mossy fiber rendered it 
an excellent model to investigate the subcellular localiza-
tion of BACE1 in vivo. Our findings provide the first une-
quivocal demonstration that BACE1 localizes to vesicles 
in large presynaptic mossy fiber terminals within CA3 in 
both normal and AD model mouse brains. In some cases, 
BACE1-immunopositive vesicles were located near active 
zones, implying an important but as yet undetermined 
function of BACE1 at the synapse. Moreover, BACE1 
was also enriched within a distinct subtype of dystrophic 
presynaptic neurite that surrounds the amyloid plaque in 
the APP transgenic brain. These BACE1-positive presynap-
tic dystrophies tended to contain fewer large electron-dense 
multilamellar autophagosomes. This was true for neuritic 
dystrophies observed within the hippocampus as well as 
in the cerebral cortex. Importantly, we observed that accu-
mulations of BACE1 and APP co-localized in presynap-
tic dystrophies, implying increased BACE1 processing of 
APP in these abnormal peri-plaque regions. In addition, 
BACE1 partially co-localized with transferrin receptor, 
suggesting that BACE1 accumulates in endosomes of 
dystrophic terminals. In primary cortical neuron cultures, 
treatment with the lysosomal protease inhibitor leupeptin 
resulted in increased BACE1 levels; however, exposure of 
neurons to the autophagy inducer trehalose did not reduce 
BACE1 levels, suggesting that BACE1 is degraded in the 
lysosomal, but not the autophagic, pathway. Though the 
precise mechanism of BACE1 accumulation within aber-
rant presynaptic dystrophies in the APP transgenic brain 
is currently unknown, our data as well as other published 
reports imply a link to decreased lysosomal degradation of 
BACE1 within dystrophic axon terminals. An increase in 
BACE1 level in plaque-associated dystrophic presynaptic 
terminals, in conjunction with APP accumulation in these 
neuritic dystrophies [19, 20], may elevate local peri-plaque 




5XFAD mice have been described previously [75] and were 
maintained on a B6/SJL F1 hybrid background. BACE1−/− 
mice on a C57/B6 background were obtained from Jack-
son Laboratories (strain #006554). Non-transgenic age-
matched B6/SJL or C57/B6 mice were used as controls. 
Procedures were performed with Northwestern University 
IACUC approval.
Tissue collection for immunoblots and confocal 
microscopy
Mice were perfused with cold phosphate buffered saline 
(PBS) containing protease and phosphatase inhibitors 
[20 μg/ml phenylmethylsulfonyl fluoride (PMSF, Sigma), 
500 ng/ml leupeptin (MP Biomedicals), 20 μM sodium 
orthovanadate (MP Biomedicals), 10 μM dithiothreitol 
(DTT, Sigma)]. A hemibrain from each mouse was dis-
sected into hippocampus and cortex and snap-frozen sepa-
rately for biochemical analyses; the other hemibrain was 
drop-fixed in 4 % paraformaldehyde overnight at 4 °C and 
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cryopreserved in 30 % (w/v) sucrose/PBS at 4 °C for his-
tology. Fixed cryopreserved human Braak stage V–VI brain 
tissues (entorhinal cortex and superior temporal gyrus) 
from three AD cases were obtained from the Cognitive 
Neurology and AD Center at Northwestern University.
Immunoblot analysis
5XFAD and non-transgenic (5 each) hippocampi were indi-
vidually homogenized in 1 % Triton X-100/PBS with 1× 
protease inhibitor (Calbiochem) and 1× Halt Phosphatase 
Inhibitor cocktail (Thermo Scientific). Protein concentra-
tion was quantified by BCA (Thermo Scientific). Hip-
pocampal homogenates (20 μg) and primary neuron lysates 
(10 μg) were separated by 12 % Tris–Glycine or 4–12 % 
Bis–Tris SDS-PAGE and transferred onto 0.45 μm PVDF 
membranes (Millipore) that were subsequently Ponceau 
stained, scanned, and probed with the following antibod-
ies recognizing BACE1 (1:1000; BACE–Cat1 [121]), 
LC3B (1:1,000 or 1:4,000; Cell Signaling #3868), and 
β-III-tubulin (TuJ1) (1:10,000; gift of Dr. Lester Binder). 
Membranes were then washed with TBST and incubated 
with the appropriate HRP-conjugated secondary antibodies 
(1:10,000; Vector Laboratories), washed again and visual-
ized using Luminata Crescendo (Millipore). Signals were 
quantified using a Kodak Image Station 4000R. Signal 
intensities were normalized to tubulin or ponceau staining 
as indicated.
Mouse immunofluorescence confocal microscopy
Free-floating hemibrain coronal sections (30 μm) from 
5XFAD and non-transgenic mice (2–3 each) were cut on 
a freezing microtome, washed in TBS, and blocked in 5 % 
goat or donkey serum. Sections were incubated at 4 °C 
overnight on a shaker with the following primary antibod-
ies: mouse monoclonal anti-BACE1 (1:250; BACE–Cat1 
[121]) or rabbit monoclonal anti-BACE1 (1:250; Epitom-
ics #EPR3956), goat polyclonal anti-synaptophysin (1:250 
mouse brain, 1:50 human brain; R&D Systems #AF5555), 
goat polyclonal anti-APP (1:500; Karen, gift of Dr. Vir-
ginia Lee), rat monoclonal anti-transferrin receptor (1:500; 
Abcam #ab60344), rat monoclonal anti-LAMP1 (1:500; 
Abcam #ab25245), mouse monoclonal anti-β-III-tubulin 
(TuJ1) (1:100; gift of Dr. Lester Binder), chicken polyclonal 
anti-microtubule-associated protein 2 (MAP2) (1:250; 
Abcam #ab5392), mouse monoclonal anti-neurofilament 
NFT160 (1:250; Sigma #N5264), rabbit monoclonal anti-
LC3B (1:500; Cell Signaling #3868). Sections treated with 
Epitomics anti-BACE1 primary antibody were incubated 
for 2 h at 37 °C on a shaker. Following primary antibod-
ies, sections were washed in TBS and incubated with Alexa 
Fluor secondary antibodies at 1:1,000 (donkey anti-mouse 
or rabbit-488 or 594; goat anti-mouse or rabbit-488 or 594) 
and DAPI (Invitrogen), washed, mounted on charged slides 
and cover-slipped using ProLong Gold (Invitrogen). Images 
were captured on Nikon (Tokyo, Japan) A1R or Zeiss LSM 
510 laser scanning confocal microscopes.
Human immunofluorescence confocal microscopy
Human AD sections were processed using the same method 
as mouse, with the addition of antigen retrieval and autoflu-
orescence reduction steps. Free-floating sections (40 μm) 
from 3 Braak stage V–VI AD brains were washed in TBS 
and incubated for 1 h in 16 mM glycine on a shaker. After 
TBS washes, sections underwent antigen retrieval using 
0.1 M sodium citrate, pH 9.0, for 1.5 h at 80–90 °C, TBS 
washed, and incubated in KMnO4 until brown. Sections 
were washed with DI water, treated with 0.5 % oxalic acid 
and 0.5 % K2S2O5 to remove brown color, washed again, 
and incubated on a shaker for 30 min in 0.25 % NaBH4. 
Following a 0.25 % Triton/TBS wash, sections were 
blocked and incubated with primary antibodies as in the 
mouse immunofluorescence procedure.
Pre-embedding ultrasmall silver-intensified immunogold 
electron microscopy
Two to three adult (4–14 months) 5XFAD, non-transgenic 
(C57Bl6/SJL), and BACE1−/− mice were anesthetized 
with isoflurane (Isothesia, Butler), transcardially perfused 
with 0.9 % saline followed by 50 ml ice-cold acidic fixa-
tive (2 % paraformaldehyde, 1 % glutaraldehyde in 0.1 M 
sodium acetate, pH 6.0), then slowly perfused with ice-
cold basic fixative (2 % paraformaldehyde, 1 % glutar-
aldehyde in 0.1 M sodium borate buffer, pH 9.0) for 1 h. 
Brains were removed, placed in ice-cold basic fixative on 
a shaker at 4 °C overnight. The following day brains were 
bisected, washed 3 × 20 min in TBS, and cut into 70 μm 
coronal sections on a vibratome. Sections were washed 
in TBS 5 × 5 min, treated with 1 % NaBH4 in TBS for 
30 min, washed in TBS 5 × 1 min and incubated in block-
ing solution (10 % NGS in TBS) for 30 min followed by 
incubation in primary antibody overnight at 4 °C. Primary 
antibody [rabbit monoclonal anti-BACE1 (1:500; Cell 
Signaling #5606 or Epitomics #EPR3956); mouse mono-
clonal anti-β-III-tubulin (TuJ1) (1:100; gift from Dr. Lester 
Binder); rabbit polyclonal anti-synaptophysin (1:500; Mil-
lipore #AB9272)] was diluted in 2 % NGS + 0.1 or 0.5 % 
Triton X-100 in TBS. Sections were washed 1 × 5 min 
in incubation buffer and 10 × 5 min in TBS, then incu-
bated in secondary blocking buffer [2 % NGS + 1 % 
BSA + 0.3 % cold water fish skin gelatin (CWFSG) 
in TBS] for 1 h followed by incubation in Ultra Small 
Immunogold (Aurion) anti-rabbit secondary antibody at 
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1:100 in 2 % NGS + 1 % BSA-C + 0.3 % CWFSG at 
4 °C for ~40 h. Sections were washed in incubation buffer 
1 × 5 min, TBS 6 × 10 min, PBS 2 × 5 min then fixed in 
2 % glutaraldehyde in PBS for 1 h, followed by washes 
2 × 5 min in PBS, 4 × 10 min in TBS, and 3 × 10 min 
in enhancement conditioning solution (ECS). Sections 
were then incubated in R-Gent SE-EM Plus enhancement 
mixture for 90 min and washed in ECS 4 × 10 min, TBS 
2 × 10 min, and PBS 2 × 10 min, osmicated with 0.4 % 
OsO4 in PBS for 15 min and rinsed in PBS 3 × 10 min 
and dH2O 2 × 5 min. Sections were stained in 1 % aque-
ous uranyl acetate for 10 min, rinsed 3 × 10 min in dH2O, 
dehydrated in graded ethanol and propylene oxide, infil-
trated with 1:1 araldite:propylene oxide overnight at room 
temperature, followed by flat embedding between aclar 
sheets and curing for 48 h at 60 °C. Regions of interest 
were subdissected and re-embedded in Araldite and cured 
overnight at 60 °C. 500-nm-thick histological sections 
were cut by ultramicrotome and stained with toluidine 
blue to confirm the presence of the stratum lucidum. Serial 
ultrathin sections (63 nm) were cut with a diamond knife, 
placed onto formvar-coated slotted grids, stained with ura-
nyl acetate–lead citrate (for 15 and 10 min, respectively), 
washed in ultrapure dH2O, and allowed to dry at room 
temperature. Images were taken with a JEOL 1200EX 
electron microscope (JEOL Ltd., IL, USA) at a magnifi-
cation of 7500–20,000×. Electron micrographs from 8 to 
30 serial sections containing mossy fiber terminals or dys-
trophic neurites were obtained between 1 and 8 microns 
from the tissue surface (i.e., the surface of the 70-μm sec-
tion that was immunogold-labeled) [111]. EM reagents 
were from Electron Microscopy Sciences (Hatfield, PA) 
unless otherwise noted.
Conventional electron microscopy
One adult 5XFAD, C57/Bl6, and BACE1−/− mouse was 
anesthetized with isofluorane (Isothesia, Butler), perfused 
transcardially with 0.12 M PBS (pH 7.4) for 1 min, then 
a dilute aldehyde mixture (1 % paraformaldehyde, 1.25 % 
glutaraldehyde, 0.02 mM CaCl2 in 0.1 M sodium caco-
dylate buffer) for 30 min, and a concentrated aldehyde 
mixture (2 % paraformaldehyde, 2.5 % glutaraldehyde, 
0.04 mM CaCl2 in 0.1 M sodium cacodylate buffer) for 
10 min. Brains were removed and placed in ice-cold con-
centrated fixative on a shaker at 4 °C overnight. The fol-
lowing day brains were bisected, rinsed 3 × 20 min in 
0.12 M TBS and cut into 70 μm coronal sections as above. 
Sections were washed in 0.12 M phosphate buffer (PB) 
3 × 10 min at 4 °C, treated with 2 % OsO4 in 0.12 M PB 
for 1 h at 4 °C, and washed 3 × 10 min in 0.12 M PB. The 
tissue was then dehydrated in graded ethanols and propyl-
ene oxide, infiltrated with 1:1 araldite:propylene oxide, flat 
embedded between aclar sheets and cured for 48 h at 60 °C. 
Regions of interest were subdissected and re-embedded as 
above. Serial ultrathin sections (65 nm) were cut, placed 
onto formvar-coated slotted grids, then stained with ura-
nyl acetate–lead citrate (15 and 10 min, respectively) and 
rinsed in ultrapure dH2O. Images (7500–20,000×) were 
taken with a JEOL 1200EX electron microscope (JEOL 
Ltd., IL, USA) from 10–30 serial sections.
Primary neuron culture
Cortical neurons were isolated from day 15.5–16.5 C57/
B6 mouse embryos via dissociation at 37 °C in 0.25 % 
trypsin. Neurons were plated at a density of 750,000 cells 
per well in poly-l-lysine coated 12-well plates containing 
neurobasal media supplemented with 2 % B-27, 500 μM 
glutamine, 10 % horse serum and 2.5 μM glutamate. After 
2–3 h, the media was replaced with neurobasal media with 
2 % B-27, 500 μM glutamine, and 2.5 μM glutamate. After 
3 DIV, media was replaced with neurobasal media with 
2 % B-27 and 500 μM glutamine. All cell culture reagents 
were from Invitrogen. After 6 DIV, neurons were exposed 
to 20 μM leupeptin (MP Biomedicals), 150 mM trehalose 
(Sigma), or both for 24 or 48 h. In a separate experiment, 
neurons were treated with 100 nM bafilomycin (Sigma) for 
4 h. Neurons were lysed in RIPA buffer (150 mM NaCl, 
1 % IGEPAL CA-630, 0.5 % sodium deoxycholate, 0.1 % 
SDS, 50 mM Tris pH 8, 1 mM PMSF) with 1× protease 
inhibitors (Calbiochem) and 1× Halt Phosphatase Inhibitor 
Cocktail (Thermo Scientific). Lysates were centrifuged at 
10,000 rpm, 4 °C, 10 min and the supernatant protein was 
quantified by BCA (Thermo Scientific).
Statistical analyses
Densitometric analyses of immunoblots were performed 
using Kodak 1D 3.6 image analysis software. Statistical 
differences for immunoblot experiments were determined 
using two-tailed students t test or ANOVA (GraphPad Soft-
ware, Inc., San Diego, CA). Graphed data are presented as 
the mean ± SEM, and p < 0.05 was considered significant.
Results
BACE1 is localized in presynaptic terminals of normal 
brain at the ultrastructural level
Previously, we generated a mono-specific anti-BACE1 
antibody (BACE–Cat1) that does not cross-react with any 
other protein in the brain [121]. Initial BACE1 immuno-
histochemistry results using BACE–Cat1 suggested that 
the highest levels of BACE1 in the brain were located in 
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stratum lucidum of the CA3 hippocampal subregion [121]. 
Earlier reports indicated that BACE1 is predominantly 
expressed in neurons [40, 96, 106], although these studies 
did not determine the subcellular localization of BACE1 in 
neurons of the normal brain. To investigate BACE1 locali-
zation, we co-labeled coronal brain sections from wild-type 
mice with BACE–Cat1 and antibodies against the presyn-
aptic terminal marker synaptophysin or the somatodendritic 
marker microtubule-associated protein 2 (MAP2) and per-
formed immunofluorescence confocal microscopy (Fig. 1). 
We observed that the vast majority of BACE1 immunostain-
ing co-localized with synaptophysin labeling (Fig. 1c, f) 
and displayed a punctate pattern that represents the large 
mossy fiber terminals (MFTs/giant boutons) of dentate 
gyrus granule cell axons within the stratum lucidum region 
of CA3 (Fig. 1d). In addition, faint punctate immunolabe-
ling of BACE1 co-localized with that of synaptophysin in 
the hippocampus (Fig. 1d–f) and throughout the rest of the 
brain (not shown), indicating that BACE1 localizes gener-
ally to presynaptic terminals in the CNS. A small propor-
tion of BACE1 puncta was also seen in neuronal soma in 
the pyramidal layers of CA1 and CA3, which likely repre-
sents BACE1 localization within the trans-golgi network 
(TGN) or endosomal compartments of cell bodies (Fig. 1d, 
white arrowheads). BACE1 puncta within cell bodies did 
not co-localize with synaptophysin (Fig. 1d–f). In contrast 
to BACE1 co-localization with synaptophysin, we did not 
detect co-localization of BACE1 and MAP2 in either CA3 
(Fig. 1g–i) or CA1 (Fig. 1j–l). Taken together, our data and 
other published reports [57, 93] indicate that a large propor-
tion of endogenous BACE1 in the brain is localized within 
presynaptic neuronal terminals, but little if any BACE1 is 
present in postsynaptic areas other than the soma.
Although our BACE1 immunofluorescence confocal 
microscopy results indicated that BACE1 is predominantly 
presynaptic, light microscopy lacks the resolution to deter-
mine the precise subcellular localization of BACE1 in the 
axon terminal. Therefore, we performed serial section pre-
embedding silver-intensified ultrasmall BACE1 immuno-
gold electron microscopy (immuno-EM), as well as conven-
tional EM. We focused specifically on hippocampal MFTs 
within stratum lucidum, which serve as excellent models 
of presynaptic terminals for our BACE1 studies: they are 
large, have easily identifiable morphology [2, 15, 26, 88, 
112], and exhibit the highest concentration of BACE1 in 
the brain [121]. The ultrastructural features of MFTs allow 
for unequivocal identification by EM [2, 15, 26, 88, 112]. 
By means of conventional EM, CA3 presynaptic terminals 
from wild-type (BACE1+/+, Fig. 2a–c) and BACE1−/− 
(Fig. 2d–f) brains were morphologically indistinguishable. 
BACE1+/+ and BACE1−/− MFTs contained large vesicle 
pools densely packed with small, clear synaptic vesicles, 
some large clear vesicles, and a few intermingled dense-core 
vesicles. Mitochondria were situated along the periphery 
of the terminals, and thorny excrescences of CA3 pyrami-
dal cell dendrites invaginated the respective terminals with 
distinct postsynaptic densities. Thus, genetic ablation of 
BACE1 did not have an obvious effect on vesicle organi-
zation or gross morphology of axon terminals within the 
CA3 subregion of the murine hippocampus. This data, cou-
pled with the absence of BACE1 immunoreactivity (Suppl. 
Fig. 1b, d), rendered the BACE1−/− mouse a good negative 
control for our immuno-EM studies.
Our initial attempts at defining BACE1 localization by 
immuno-EM proved futile, as our BACE–Cat1 antibody was 
not amenable to the fixation protocol used to preserve tissue 
for electron microscopic analysis. However, with the recent 
development of superior commercial anti-BACE1 antibod-
ies, we were able to identify—with ultrastructural resolu-
tion—the precise subcellular location of BACE1 within 
the murine brain. To accomplish this, we incubated coronal 
sections of mouse hippocampus with a rabbit monoclonal 
anti-BACE1 antibody and goat anti-rabbit IgG conjugated 
to ultrasmall gold particles followed by silver enhancement, 
as previously described [60, 111]. As expected [57, 121], 
immunogold particles for BACE1 were concentrated within 
the hilar region of the dentate gyrus, the infrapyramidal bun-
dle, and stratum lucidum of CA3, an exact match to the pre-
viously observed BACE1 immunofluorescence labeling pat-
tern (Suppl. Fig. 1a, c). As a negative control to demonstrate 
antibody specificity, hippocampal sections from BACE1−/− 
mice treated with the anti-BACE1 antibody lacked BACE1 
immunoreactivity using either the immunofluorescence or 
immunogold staining protocol (Suppl. Fig. 1b, d).
When we used electron microscopy to localize 
BACE1 immunogold particles within the stratum luci-
dum of BACE1+/+ mice, we observed robust BACE1 
immunoreactivity within the large presynaptic terminals 
of the mossy fibers that synapse onto the thorny excres-
cences and proximal dendrites of CA3 pyramidal neurons 
(Fig. 3a–m). We detected heterogeneity amongst the level 
and spatial distribution of BACE1 immunogold particle 
labeling throughout different mossy fiber terminal fields. 
Importantly, the vast majority of BACE1 immunogold was 
localized over areas that exhibited the densely packed syn-
aptic vesicles that we observed in MFTs by conventional 
EM (Fig. 2), although there were no obvious morphologi-
cal characteristics distinguishing immunopositive from 
immunonegative vesicles. Occasionally, gold particles 
were projected onto vesicles very near the active zone of 
a synapse (Fig. 3f, g, red arrowheads). Though the vast 
majority of immunogold labeling was presynaptic, a very 
small number of postsynaptic gold particles were noted 
that we suspected might have represented background. 
This suspicion was supported by the presence of occa-
sional gold particles observed in postsynaptic elements 
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Fig. 1  BACE1 is localized within presynaptic terminals at the light 
microscopic level. Representative images of coronal brain sections 
from 2- to 3-month-old wild-type mice co-stained with BACE1 (red) 
and synaptophysin or MAP2 (green) antibodies and imaged by laser 
scanning confocal microscopy. a–c At low magnification, BACE1 
immunoreactivity is observed in the hilar region of the dentate gyrus 
(H), and in the infrapyramidal bundle (IPB) and stratum lucidum (SL) 
of the hippocampal mossy fiber pathway, where extensive co-labeling 
with synaptophysin also occurred, denoting presynaptic localization 
of BACE1 within these brain regions. d–f Higher magnification of 
BACE1 and synaptophysin immunoreactivity within the stratum luci-
dum of the wild-type mouse shown in a–c. BACE1 and synaptophy-
sin signals significantly co-localize within mossy fiber terminals in f. 
Note the punctate BACE1 signals within neuronal soma (examples 
indicated by white arrowheads), which do not overlap with synapto-
physin immunoreactivity and likely represent TGN and endosomes. 
g–l BACE1 immunoreactivity does not overlap with that of the soma-
todendritic marker MAP2 (green) within the stratum lucidum in CA3 
(g–i) or the stratum radiatum in CA1 (j–l). Scale bar a–c, 200 μm; 
d–l, 25 μm
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within BACE1−/− brains, which otherwise lacked BACE1 
immunogold labeling within presynaptic compartments 
(Fig. 3n–p). Taken together, our BACE1 immunofluores-
cence and immuno-EM results unequivocally demonstrate 
that endogenous BACE1 is predominantly localized to the 
presynaptic terminal in the normal murine hippocampus. 
In addition, our data suggest that BACE1 is present in 
vesicles, some in close proximity to synaptic active zones, 
although the exact identity of BACE1-containing vesicles 
has yet to be determined.
BACE1 is localized within endocytic vesicles of dystrophic 
presynaptic terminals in the APP transgenic brain at the 
ultrastructural level
Previously, we determined that BACE1 levels are elevated 
in the brains of humans with AD and APP transgenic mice 
[121]. Moreover, we observed that BACE1 accumulates in 
synaptophysin-positive structures surrounding the cores of 
amyloid plaques. However, that study did not determine 
the precise identity and ultrastructure of the BACE1- 
containing entities. To accomplish this, we performed immu-
nofluorescence confocal microscopy, conventional EM, 
and serial section pre-embedding immuno-EM as before, 
on hippocampal and cortical sections from the brains of 
the 5XFAD mouse model of AD, which displays memory 
impairments and development of amyloid plaques [75] that 
are consistent with human AD pathology. As with wild-
type mice, 5XFAD mice exhibited high levels of BACE1 
within the hilar region of the dentate gyrus, the infrapyram-
idal bundle, and stratum lucidum of the hippocampus via 
immunofluorescence confocal microscopy (Fig. 4a). More-
over, BACE1 immunoreactivity was aberrantly localized to 
an annulus surrounding each amyloid plaque (Fig. 4d, g), 
also consistent with our previous findings as well as oth-
ers [12, 105, 120, 121]. BACE1 immunostaining around 
plaques generally had a punctate appearance (e.g., Fig. 4g), 
suggesting vesicular localization, as expected [106]. Impor-
tantly, 5XFAD hippocampal sections co-stained with anti-
bodies against APP and BACE1 revealed significant co-
localization (Fig. 5a–c). These results demonstrate that 
the BACE1 enzyme and APP substrate both accumulate in 
overlapping areas in close proximity to amyloid plaques, 
precisely where elevated BACE1 cleavage of APP could 
lead to locally increased Aβ production and exacerbation of 
amyloid pathology.
Fig. 2  BACE1−/− mossy fiber terminals have normal ultrastruc-
ture. Serial ultrathin sections of the stratum lucidum from 5-month-
old BACE1+/+ (a–c) and 11-month-old BACE1−/− (d–f) mice were 
imaged by electron microscopy. Shown are representative single 
presynaptic mossy fiber terminals (MFTs) contacting postsynaptic 
thorny excrescences (TE) with clearly recognizable synapses (bands 
of electron-dense material). Note the compact pool of synaptic vesi-
cles distributed throughout the terminals. A high abundance of small, 
clear presynaptic vesicles can be resolved, as well as a lower abun-
dance of large clear vesicles (red arrowheads) and dense-core vesi-
cles (blue arrows). Mitochondria (m) of various shapes and sizes are 
located near the plasma membranes of the MFTs. No morphological 
differences in MFTs are evident between BACE1+/+ and BACE1−/− 
mice. Scale bars 200 nm
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Previous studies in both rodents and in humans have 
shown that many of the structures encircling plaques are 
dystrophic presynaptic terminals [9, 65, 66, 89, 121], 
though distended postsynaptic elements may also appear 
nearby plaques [6]. We have previously shown that many 
BACE1-positive dystrophies are engorged presynaptic 
337Acta Neuropathol (2013) 126:329–352 
1 3
structures in the AD and 5XFAD brain [121]. Using 
immunofluorescence confocal microscopy, we likewise 
demonstrated that BACE1 immunoreactivity overlapped 
that of synaptophysin within many of the neuritic dys-
trophies adjacent to amyloid plaques (Fig. 4d–f). Con-
versely, BACE1-positive structures did not co-localize 
with the somatodendritic marker MAP2 (Fig. 4g–i) [121]. 
To determine the extent to which this pattern of BACE1 
localization in 5XFAD brain recapitulated that in human 
AD brain, we performed BACE1 and synaptophysin 
(Fig. 4j–l) or MAP2 (Fig. 4m–o) co-staining of AD hip-
pocampal sections followed by immunofluorescence con-
focal microscopy. Similar to the 5XFAD brain, BACE1 
and synaptophysin displayed significant co-localization 
surrounding amyloid plaques, while MAP2 did not over-
lap with BACE1 in the AD brain. These results support 
our previous work [121] and confirm that 5XFAD mice are 
faithful models of amyloid-associated BACE1 elevation in 
AD.
To further characterize the pattern of BACE1 accumu-
lation surrounding amyloid plaques, we co-stained 5XFAD 
brain sections with anti-BACE1 and antibodies that recog-
nize either neuron-specific class III β-tubulin (Fig. 5d–f) 
or α-tubulin (Fig. 5g–i), which comprise microtubules. 
Interestingly, BACE1 showed minimal co-localization with 
β-tubulin or α-tubulin, suggesting that regions of BACE1 
accumulation had reduced levels of microtubules. Moreo-
ver, a significant proportion of α- and β-tubulin staining 
around plaques was concentrated in aberrant spherical, 
oblate, or ring-like structures (Fig. 5e, h, arrowheads); 
such structures are unlikely to contain normal bundles of 
functional microtubules. Given the evidence of abnormal 
cytoskeletal elements in peri-plaque regions [8], we addi-
tionally co-labeled 5XFAD brain sections with antibodies 
against neurofilament (NFT), a major axonal cytoskeleton 
component, and BACE1. A 3-dimensional reconstruction 
of an immunofluorescence confocal microscopy z-series 
showed extensive labeling of axons coursing through 
brain tissue, with some axons ending as engorged bulbous 
structures that also contained BACE1 immunoreactivity 
(Fig. 5j). Thus far, our data indicated that (1) BACE1 local-
izes to normal mossy fiber terminals of hippocampal region 
CA3; (2) BACE1 accumulates in dystrophic presynaptic 
axon terminals surrounding amyloid plaques in the AD and 
5XFAD brain; (3) little if any BACE1 localizes to postsyn-
aptic structures, and (4) aberrant microtubule structures are 
present in regions that lack BACE1.
To investigate the nature of the BACE1-containing 
dystrophies at the ultrastructural level, we performed con-
ventional EM and immuno-EM of 5XFAD hippocampal 
sections, as described above. First, we examined the ultra-
structure of normal MFTs in the 5XFAD brain. Despite the 
abundance of distended neuronal processes surrounding 
plaques, neighboring MFTs were morphologically com-
parable to those observed in wild-type and BACE1−/− 
brains by conventional EM (Fig. 6). These vesicle-rich 
axon terminals contained numerous small clear vesicles, 
and to a lesser extent some large clear vesicles and dense-
core vesicles (Fig. 6b, c). Dendrites and thorny excres-
cences protruded into MFTs, making synaptic contacts, 
and mitochondria aligned along the inside border of the 
plasma membrane of the axon terminal. To ultrastructur-
ally localize BACE1 in the 5XFAD brain, we turned again 
to immuno-EM. Light microscopic examination of pre-
embedding silver-intensified BACE1 immunogold in the 
5XFAD hippocampus revealed BACE1 immunoreactivity 
in stratum lucidum, the IPB and hilar region of the dentate 
gyrus (Suppl. Fig. 2a,), which was consistent with fluores-
cent BACE1 immunolabeling (Fig. 4a). At the EM level, 
BACE1 immunogold particles were predominantly located 
within presynaptic compartments in stratum lucidum, with 
variable signal intensity and distance from active zones 
within a given axon terminal (Suppl. Fig. 2b–g). These 
results mirror the presynaptic pattern of BACE1 localiza-
tion within MFTs of wild-type mice.
In the electron microscope, distended neuronal pro-
cesses in the 5XFAD hippocampus were readily apparent at 
low magnification (Figs. 6a, 7a). These abnormal, swollen 
neurites were invariably near plaques and appeared analo-
gous to those observed in other AD mouse models [8, 23, 
56, 67, 76, 89, 119] as well as human AD brains [45, 66, 
72, 92, 100]. Moreover, the 5XFAD neuritic dystrophies 
were densely packed with lamellar structures of variable 
morphology and size (Figs. 6a, 7). Dystrophic neurites 
have been shown to be positive for markers of autophagy 
[14, 45, 72] and are typically filled with an abundance of 
autophagic intermediates, as viewed at the EM level [8, 
23, 45, 56, 67, 72, 76, 89, 100, 119]. Indeed, many of the 
lamellar structures in the 5XFAD dystrophies were mor-
phologically similar to autophagosomes observed in human 
AD and AD mouse models.
Fig. 3  BACE1 is localized within mossy fiber terminals at the elec-
tron microscopic level. Coronal brain sections from 4- to 14-month-
old BACE1+/+ (a–m) and BACE1−/− (n–p) mice were processed 
for BACE1 pre-embedding silver-intensified ultrasmall immunogold 
and then serial ultrathin sections of the stratum lucidum were imaged 
by electron microscopy. a–p Representative serial images of single 
mossy fiber terminals. BACE1 immunoreactivity is clearly enriched 
within presynaptic terminals, although there is heterogeneity in the 
abundance of gold particles within a given terminal as well as dis-
tance from synapses (bands of electron-dense material). In some 
cases, BACE1 immunogold particles are located in close proximity to 
an active zone (f, g red arrowheads). Postsynaptic regions (dendrites 
and thorny excrescences, shaded yellow) contain little to no BACE1 
immunoreactivity. n–p BACE1 immunogold particles are absent from 
presynaptic terminals in BACE1−/− mice, although rare background 
particles (in this case, postsynaptic) are present. Scale bars 200 nm
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Upon further inspection of BACE1 immunogold-labeled 
5XFAD sections, ultrastructurally there appeared to be 
two subtypes of dystrophic neurites that we will refer 
to as Type I and Type II (Fig. 7). Type I dystrophies con-
tained numerous small round, oval, or irregularly shaped 
membraneous structures densely packed into an enlarged 
membrane-bound neurite. Type II dystrophies were dis-
tended membrane-bound neurites filled with large vacuolar 
structures of varying morphologies, many of which resem-
bled autophagosomes with electron-dense centers that were 
encircled by at least a single or multiple concentric mem-
branes. The amount of electron-dense material varied from 
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one vacuolar structure to another, and in general Type II 
neurites appeared more electron dense than Type I neurites. 
The two neuritic subtypes surrounded amyloid plaques in 
both hippocampus and cortex of the 5XFAD brain. Mito-
chondria were also present in both subtypes. Although 
5XFAD dystrophic neurites generally could be classified as 
either Type I or Type II, we observed that some dystrophies 
contained variable mixtures of vesicular structures found in 
both subtypes, suggesting that a continuum of neuritic mor-
phologies might exist between Type I and Type II neurites. 
Interestingly, the smaller, less electron-dense vesicles of 
the Type I neurites were often immunoreactive for BACE1, 
whereas the larger, more electron-dense vesicles of the 
Type II neurites exhibited considerably less BACE1 immu-
nogold labeling (Fig. 7). Overall, these findings support our 
immunofluorescence confocal microscopy results showing 
variable, non-uniform BACE1 immunosignal intensity in 
different dystrophic neurites surrounding plaques in the AD 
and 5XFAD brain (Fig. 4).
Based on our BACE1-synaptophysin immunofluores-
cence co-localization results, we hypothesized that the 
BACE1-positive Type I dystrophic neurites were likely to 
be presynaptic structures. To explore this possibility, we 
immunogold-labeled 5XFAD brain sections with an anti-
synaptophysin antibody and determined whether morpho-
logically defined Type I dystrophies were synaptophysin-
positive. As expected, our electron microscopic analysis 
revealed enrichment of synaptophysin immunogold par-
ticles within normal mossy fiber presynaptic terminals 
(Fig. 8a–c). Moreover, synaptophysin immunoreactivity 
was detected within neuritic dystrophies (Fig. 8d), consist-
ent with other published reports [9, 65, 66, 89, 121]. These 
synaptophysin-positive dystrophies predominantly con-
tained smaller, electron translucent vesicles and therefore 
resembled BACE1-positive Type-I dystrophic neurites. We 
additionally labeled 5XFAD sections with a neuron-spe-
cific class III β-tubulin antibody. Dystrophic neurites were 
largely devoid of β-tubulin immunogold particles; however, 
dendrites were clearly immunopositive for β-tubulin in the 
5XFAD brain (Fig. 8e–n). Other reports also have shown 
that plaque-associated dystrophic neurites lack MAP2 
immunoreactivity [8, 89]. Together, these results support 
the conclusion that the abnormal, swollen structures in the 
5XFAD brain were dystrophic presynaptic terminals.
Next, we wanted to determine the type of vesicles within 
which BACE1 resides in dystrophic neurites that surround 
amyloid plaques. Therefore, we performed immunofluo-
rescence confocal microscopy of 5XFAD brain sections to 
co-localize the late endosome/lysosome marker lysosomal-
associated membrane protein 1 (LAMP1), and the early 
endosome marker transferrin receptor, along with BACE1 
(Fig. 9). BACE1 in dystrophic neurites co-localized signifi-
cantly with transferrin receptor (Fig. 9a–c), suggesting that 
a large proportion of BACE1 resides within endosomes/
endocytic compartments. In contrast, BACE1 exhibited 
relatively little co-localization with LAMP1 within a given 
neuritic dystrophy (Fig. 9d–f). Taken together, these data 
suggest that BACE1 resides primarily within endosomal 
vesicles, rather than lysosomes, within dystrophic neurites 
in the 5XFAD brain.
BACE1 is degraded by lysosomes, not by autophagy
Thus far, our confocal and electron microscopy results sug-
gested that BACE1 is localized within endocytic vesicles 
that accumulate in a subtype of dystrophic presynaptic ter-
minal surrounding amyloid plaques. In addition, our EM 
data, especially in the Type II dystrophies, clearly indicated 
an accumulation of autophagic intermediates, consistent 
with EM reports of human AD and other AD mouse mod-
els, suggesting elevated autophagy in the 5XFAD brain. 
To confirm this biochemically, we performed immuno-
blot analysis for a marker of autophagosomes, LC3B-II 
[3], in hippocampal homogenates of 6-month-old 5XFAD 
mice and non-transgenic littermates (Fig. 10). During 
autophagy, LC3B-I is conjugated with phosphatidylethan-
olamine to form LC3B-II, which becomes associated with 
the autophagic membrane and changes from diffuse to 
punctate intracellular localization [41]. We observed a dra-
matic increase in the immunoblot signal ratio of LC3B-II 
to LC3B-I (~9-fold) in 5XFAD hippocampal homogen-
ates (Fig. 10a, b), consistent with the accumulation of 
Fig. 4  BACE1 accumulates presynaptically around amyloid plaques 
in 5XFAD transgenic mouse and human AD brains. Representative 
images of sections from 5XFAD transgenic mouse (~6 months old) 
or human AD brains co-stained with BACE1 (red) and synaptophy-
sin or MAP2 (green) antibodies and imaged by laser scanning con-
focal microscopy. a–c At low magnification, in addition to normal 
BACE1 localization in hippocampal mossy fibers, BACE1 immuno-
reactivity (red) displays a plaque-like staining pattern that overlaps 
with synaptophysin (green) immunoreactivity in the 5XFAD brain 
(white arrowheads indicate representative plaque). d–f Higher mag-
nification images showing extensive co-localization of BACE1 and 
synaptophysin around amyloid plaques (white asterisks) in 5XFAD 
brain, demonstrating accumulation of BACE1 in abnormal presyn-
aptic structures, likely dystrophic terminals (white arrowheads indi-
cate representative dystrophies with BACE1-synaptophysin co-local-
ization). g–i No overlap between BACE1 and the somatodendritic 
marker, MAP2 (green), is apparent in dystrophic structures surround-
ing plaque cores stained with thioflavin S (blue). Superior temporal 
gyrus or entorhinal cortex brain sections of Braak stage V–VI human 
AD brains were co-stained with antibodies against BACE1 (red) and 
synaptophysin (j–l) or MAP2 (m–o) (green). BACE1 immunoreac-
tivity overlaps with that of synaptophysin (j–l) but not MAP2 (m–o) 
within some of the abnormal structures near plaques in human AD 
(e.g., white arrowheads). Although immunostaining was somewhat 
weaker in AD compared to 5XFAD brain sections, both exhibited 
qualitatively similar patterns of presynaptic BACE1 accumula-
tion around plaques. Scale bars a–c, 200 μm; d–f, j–o, 20 μm; g–i, 
25 μm
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Fig. 5  BACE1 co-localizes with APP and neurofilament, but not 
tubulin, around plaques in the 5XFAD brain. Coronal brain sections 
from ~6-month-old 5XFAD mice were co-stained with antibod-
ies against BACE1 and either APP, β-tubulin, α-tubulin, or medium 
neurofilament (NFT160) and imaged by laser scanning confocal 
microscopy. a–c BACE1 immunoreactivity (red) exhibits variable 
but significant overlap with that of APP (green) within dystrophies 
around thioflavin S-positive plaques (blue), suggesting that APP 
could be processed by BACE1 in these abnormal structures. In con-
trast, BACE1 and β-tubulin (d–f) and α-tubulin (g–i) immunoreac-
tivities display largely non-overlapping patterns around plaques. e, 
h Note that irregular spherical accumulations of tubulin are observed 
nearby plaques (arrowheads). j Sequential z axis images of BACE1 
(white) and medium neurofilament (red) immunoreactivities were 
taken and subsequently stacked in Nikon Elements with alpha-blend-
ing. BACE1 co-localizes with neurofilament in a dystrophic neurite 
(dotted white line). Importantly, the process of the neurite, immunola-
beled for neurofilament, ends in a dystrophy, likely an axon terminal. 
Scale bars a–i, 20 μm; Dimensions for box in j: width, 181.41 μm; 
height, 181.41 μm; depth, 22.80 μm
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autophagic intermediates and a recent report also showing 
an increased LC3B-II: LC3B-I ratio in an APP transgenic 
[89]. In addition, confocal microscopy of 5XFAD cortex 
showed punctate LC3B immunostaining surrounding amy-
loid plaques in a pattern that exhibited minimal co-localiza-
tion with BACE1 labeling (Fig. 10d–f), reminiscent of the 
distribution of BACE1-negative autophagosomes in Type 
II dystrophic neurites by EM. Immunoblot analysis also 
revealed that BACE1 levels were significantly increased 
in the hippocampi of 5XFAD mice compared to non-
transgenic littermates (Fig. 10a, c), similar to our previous 
reports [74, 121]. These elevations of LC3B-II and BACE1 
levels by immunoblot and immunofluorescence microscopy 
corroborate our electron microscopy data demonstrating 
the accumulation of autophagosomes and BACE1 in dys-
trophic neurites, and may reflect either impaired clearance 
of autophagosomes, increased induction of autophagy, or a 
combination of both in the 5XFAD brain.
A major goal of our study was to gain insight into the 
mechanism of BACE1 elevation in AD. Given our results 
that both autophagy and BACE1 were increased in the 
5XFAD brain, we tested the hypothesis that BACE1 is a 
substrate of autophagy; if so, BACE1 elevation could arise 
from failure of autophagy to clear BACE1. To determine 
whether BACE1 is degraded by autophagy, we treated 
primary murine cortical neurons with two inducers of 
autophagy, rapamycin [73] and trehalose [90], and the lyso-
somal protease inhibitor leupeptin, followed by immunob-
lot analysis for BACE1 and LC3B. Leupeptin was used to 
test the alternative hypothesis that BACE1 is degraded by 
lysosomes. While rapamycin failed to induce autophagy in 
primary neurons (data not shown), as reported previously 
[54], trehalose treatment for either 24 or 48 h dramati-
cally increased the LC3B-II:LC3B-I ratio (~7-fold by 48 h) 
compared to vehicle (Fig. 10g–h), an increase similar to 
that observed in the 5XFAD brain (Fig. 10a, b). Although 
leupeptin treatment also increased LC3B-II:LC3B-I ratio, 
supporting previous work that inhibition of lysosomal func-
tion results in decreased clearance of autophagosomes [48, 
53, 101], it did so to a much lesser extent than trehalose 
(Fig. 10g–h). Combined leupeptin plus trehalose treatment 
did not markedly increase LC3B-II:LC3B-I ratio beyond 
that of trehalose alone. Importantly, immunoblot analysis 
revealed that, compared to vehicle, trehalose treatment did 
not reduce BACE1 levels in primary neurons (Fig. 10g, i), 
suggesting that BACE1 is not degraded in the autophagic 
Fig. 6  Swollen dystrophic neurites form near amyloid plaques in 
the 5XFAD brain. a Low magnification electron microscope image 
of a plaque (P) surrounded by dystrophic neurites (dotted black 
lines) in the stratum lucidum of the CA3 hippocampal subregion of 
a 14-month-old 5XFAD mouse. Note that many of the dystrophic 
neurites are filled with vesicles that contain electron-dense material. 
Neighboring dendrites (d), preterminal mossy fiber bundles (PTB), 
and presynaptic terminals (white asterisks) appear normal. b, c High 
magnification electron microscope serial images of a single normal 
appearing mossy fiber terminal from the 5XFAD mouse. The ves-
icle-rich presynaptic terminal makes synaptic contact with a thorny 
excrescence (TE) and a dendrite (d) and contains an abundance of 
small clear vesicles, as well as some large clear vesicles (red arrow-
heads) and dense-core vesicles (blue arrows). Mitochondria (m) align 
near the plasma membrane of the terminal. Scale bars a, 1 μm; b–c, 
200 nm
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pathway. Interestingly, BACE1 levels in primary neurons 
treated with leupeptin were increased to over 200 % of 
vehicle by 48 h (Fig. 10g, i), a BACE1 elevation similar 
in magnitude to that observed in the 5XFAD (Fig. 10a, c) 
and the AD brain. A similar increase in BACE1 level was 
obtained by treating neurons with bafilomycin, an inhibi-
tor of endosome/lysosome acidification (data not shown). 
These results are consistent with previous reports showing 
that BACE1 is trafficked to the lysosome for degradation 
[51, 103]. Combined leupeptin plus trehalose treatment 
Fig. 7  BACE1 is localized within an electron-translucent subtype 
of plaque-associated dystrophic neurite. Coronal brain sections from 
4- to 14-month-old 5XFAD mice were processed for BACE1 pre-
embedding silver-intensified ultrasmall immunogold and then serial 
ultrathin sections of the stratum lucidum and cortex were imaged 
by electron microscopy. a Low magnification image of an amy-
loid plaque (P) surrounded by dystrophic neurites in the hippocam-
pal CA3 subregion of the 5XFAD brain. b Higher magnification of 
boxed region in a showing BACE1-positive and BACE1-negative 
dystrophic neurites. Two types of dystrophic neurites are apparent, 
which we refer to as Type I (red dotted line) and Type II (black dot-
ted lines). The different subtypes are distinguishable by the amount of 
electron density (Type I, less; Type II, more) and the size of vesicu-
lar structures (Type I, smaller vesicles; Type II, larger vesicles). Note 
that BACE1 immunogold labeling is more prominent in Type I dys-
trophic neurites (red dotted lines). c–e Representative images of serial 
ultrathin sections of BACE1 immunogold-labeled cortical neuritic 
dystrophies from the 5XFAD brain, with Type I dystrophic neurites 
predominantly enriched with BACE1 immunogold particles (red dot-
ted lines) adjacent to Type II dystrophic neurites (black dotted lines). 
f–h Representative serial images of a BACE1-immunopositive Type 
I dystrophic neurite (red dotted lines) adjacent to an aberrant den-
drite (d) and Type II dystrophic neurite (black dotted lines) within 
CA3. Note the Type II dystrophic neurite contains very few BACE1 
immunogold particles. Close examination of the aberrant dendrite (d) 
reveals abnormal microtubule organization exhibiting a swirling pat-
tern. Scale bars a, 2 μm; b, 1 μm; c–e, 200 nm; f–h, 1 μm
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produced a small but significant increase of BACE1 level 
by 48 h compared to trehalose alone (Fig. 10g, i). Taken 
together, our findings support the conclusion that BACE1 
is not cleared by autophagy, but instead is degraded in 
lysosomes, at least in primary cortical neurons in culture. 
Further, these cell culture data suggest that decreased lyso-
somal function could lead to both elevations of BACE1 and 
autophagy in AD.
Fig. 8  Type I dystrophic neurites are immunoreactive for the presyn-
aptic marker synaptophysin, but not β-tubulin. Coronal brain sections 
from ~6-month-old 5XFAD mice were processed for pre-embedding 
silver-intensified ultrasmall immunogold for synaptophysin (a–d) or 
β-tubulin (e–n) and then serial ultrathin sections of the stratum luci-
dum were imaged by electron microscopy. a–c Representative serial 
images of a single normal mossy fiber terminal exhibiting synapto-
physin immunogold particle labeling. Note that synaptophysin immu-
noreactivity is absent in the adjacent postsynaptic dendrite (yellow 
shading). d Representative image of Type I dystrophic neurites (black 
dotted lines) that are labeled with synaptophysin immunogold par-
ticles, indicating that they are presynaptic structures. e–j Images of 
serial ultrathin sections labeled with β-tubulin immunogold particles. 
Note that dendrites (yellow shading) are positive for β-tubulin, while 
the dystrophic neurite (black dotted lines) lacks β-tubulin immunore-
activity. k–n Other serial images of a representative β-tubulin immu-
nogold labeled dendrite (yellow shading). β-Tubulin immunoreac-
tivity is absent from surrounding mossy fiber terminals. Scale bars 
500 nm
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Discussion
BACE1 in the normal presynaptic terminal
BACE1 is required for Aβ generation. Thus, it is a promis-
ing AD therapeutic target (reviewed in [44, 107]). However, 
the numerous BACE1 substrates [30, 55, 123] and complex 
phenotypes of BACE1 null mice suggest that the inhibi-
tion of BACE1 for AD may not be free of mechanism-
based toxicity. Thus, knowledge of BACE1 physiological 
functions is necessary to predict and potentially avert side 
effects of BACE1 inhibitor drugs.
One poorly understood question is the role of BACE1 in 
the brain, the target organ of BACE1 inhibitors. Although 
BACE1−/− mice indicate that BACE1 is involved in mem-
ory [57, 77, 78], myelination [37, 113], seizure [33, 39, 
50], axon guidance [13, 32, 85], emotions [57], schizo-
phrenia [91] and vision [11], the mechanisms of these 
BACE1 null neurological phenotypes are not fully under-
stood. The subcellular localization of BACE1 in the brain 
may provide important clues as to the roles of BACE1 in 
the CNS and the molecular and cellular bases of BACE1 
functions.
Thus, we have investigated BACE1 cerebral localiza-
tion at both light and electron microscopic levels. To our 
knowledge, this is the first study to determine the subcel-
lular localization of endogenous BACE1 in neurons of the 
brain. Our previous work suggested that BACE1 is concen-
trated in presynaptic terminals, especially in mossy fibers 
of the stratum lucidum in hippocampal CA3 [121]. Using 
mono-specific anti-BACE1 antibodies, we performed 
immunofluorescence confocal microscopy and determined 
that BACE1 is highly localized within synaptophysin-pos-
itive puncta in large mossy fiber terminals (giant boutons) 
of CA3. Little if any BACE1 is localized to MAP2-positive 
somatodendritic postsynaptic sites in the hippocampus, 
although BACE1-positive puncta are found in neuronal 
soma (TGN, endosomes).
Immuno-EM revealed that BACE1 is localized to vesi-
cles within mossy fiber terminals. BACE1-positive vesicles 
were located near synaptic active zones, although this was 
not always the case. The specific localization of BACE1 to 
membranous vesicular structures within presynaptic termi-
nals suggests an important but as yet undetermined func-
tion of BACE1 substrate processing at the synapse. As 
with our immunofluorescence confocal microscopy, only 
Fig. 9  BACE1 co-localizes with the endosomal marker transferrin 
receptor, but not with the lysosomal marker LAMP1, in dystrophic 
neurites. Representative images of brain sections from ~6-month-old 
5XFAD mice co-stained with BACE1 (red) and transferrin receptor 
(TfR) or LAMP1 (green) antibodies and imaged by laser scanning 
confocal microscopy. a–c BACE1 exhibits significant co-localization 
with TfR in endosomes (e.g., white arrowheads) within dystrophic 
neurites surrounding an amyloid plaque (white asterisk). d–f In 
contrast, BACE1 immunoreactivity occurs in a largely non-overlap-
ping pattern with that of the late endosome/early lysosome marker, 
LAMP1, in dystrophic neurites that surround an amyloid plaque 
(white asterisk). Note that dystrophic neurites immunopositive for 
LAMP1 typically display minimal BACE1 immunoreactivity, and 
vice versa. The reason for this is unknown, but could occur if BACE1 
undergoes degradation in lysosomes, thus destroying the BACE1 
epitope. Blue in c, f indicates DAPI stain for nuclei and plaque cores. 
Scale bar 20 μm
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background BACE1 immunogold was observed postsynap-
tically. Taken as a whole, our results demonstrate that the 
presynaptic terminal is the principal site of BACE1 locali-
zation in the brain.
The function of BACE1 in the presynaptic terminal is 
currently unknown. In tissue culture cells, overexpressed 
BACE1 mainly resides in acidic compartments (TGN, 
endosomes) where BACE1 substrate cleavage occurs. 
Endosomes within presynaptic terminals have been 
reported [42, 87, 110] and although they have not been 
extensively studied, evidence suggests that presynaptic 
endosomes are involved in neurotransmitter vesicle recy-
cling [10, 28, 35, 82, 86]. Further investigation of presyn-
aptic endosomes may reveal the role of BACE1 within this 
compartment, which may reflect the need for proteolytic 
processing of one or more BACE1 substrates at or near the 
synapse. Three BACE1 substrates that may be cleaved in 
the presynaptic terminal are Navβ2, CHL1, and neuregu-
lin, which play a role in axon depolarization [46], neurite 
outgrowth/axon guidance [32] and myelination [37, 113], 
respectively. Presumably, BACE1-cleaved Navβ2 and neu-
regulin fragments would be trafficked from the presynaptic 
terminal to the axon via retrograde transport to exert their 
effects. However, BACE1 presynaptic localization argues 
that a different substrate(s) is processed by BACE1 in the 
terminal where it may perform a function required specifi-
cally at that location.
One such BACE1 substrate is APP, which has been 
hypothesized to play a role in neuroprotection [29], cell 
adhesion [99, 117], neurite outgrowth (reviewed in [104]), 
synapse formation or maintenance [80], as well as regulat-
ing synaptic transmission [43]. APP is transported to the 
neuronal terminal [52, 97] where it is likely processed by 
BACE1 and γ-secretase to generate secreted APP ectodo-
main (APPsβ), APP C-terminal fragment (β-CTF), and Aβ 
[40, 64, 96, 106, 118]. It is possible that APPsβ released 
at the terminal may function to protect or maintain synap-
tic contacts. An intriguing alternative hypothesis is that Aβ 
itself may be involved in synaptic function or neurotrans-
mission. Neuronal stimulation causes secretion of Aβ at 
the terminal [18], a process that requires endocytosis [17]. 
Other studies suggest that Aβ may regulate glutamater-
gic synaptic transmission [16] and facilitate LTP [83, 84, 
115, 116] at low endogenous Aβ concentrations normally 
released at the terminal. Thus, BACE1 in the presynaptic 
terminal may serve to process APP into Aβ for the latter’s 
presumptive role in synaptic function.
Another interesting BACE1 substrate that may func-
tion at the presynaptic terminal is CHL1 [32, 55, 123]. 
Importantly, BACE1−/− axon guidance defects in the 
hippocampus and olfactory bulb phenocopy axon tar-
geting errors observed in CHL1−/− mice [31, 32, 68]. 
Moreover, CHL1 is processed by BACE1, and CHL1 and 
BACE1 co-localize in primary neuron growth cones and 
in presynaptic terminals in hippocampus and olfactory 
bulb [32], suggesting that BACE1 cleavage of CHL1 is 
necessary for proper axon guidance. The action of other 
BACE1 substrates at the terminal could also explain 
BACE1 presynaptic localization. Numerous BACE1 sub-
strates have been identified [30, 55, 123] and others will 
likely be discovered in the future. Additional studies will 
be necessary to validate putative BACE1 substrates in 
vivo and thereby clarify the role of BACE1 in the presyn-
aptic terminal.
BACE1 in the dystrophic presynaptic terminal surrounding 
the amyloid plaque
Several studies report that BACE1 levels are elevated in 
AD brains [27, 34, 62, 121]. These results raise two intrigu-
ing questions: (1) Does BACE1 elevation exacerbate AD 
pathogenesis? (2) What mechanism is responsible for 
BACE1 elevation? These questions have potential implica-
tions for AD mechanisms and novel therapeutics. To gain 
insight into the second question, we performed immuno-
fluorescence confocal and immunogold electron micros-
copy to determine where cerebral BACE1 accumulates in 
the 5XFAD transgenic mouse model of amyloid pathol-
ogy. BACE1 immunofluorescence confocal microscopy 
and immuno-EM of 5XFAD brain sections showed endog-
enous BACE1 localization within normal CA3 mossy fiber 
presynaptic terminals with occasional BACE1 labeling near 
active zones. In addition, BACE1 accumulates within pre-
synaptic dystrophies that surround amyloid plaques within 
the hippocampus and cortex. Importantly, APP exhibited a 
high degree of co-localization with BACE1 in 5XFAD pre-
synaptic dystrophic neurites, suggesting the intriguing pos-
sibility that BACE1 processing of APP might occur in these 
dystrophies to exacerbate Aβ generation and plaque forma-
tion. APP has been reported to localize within dystrophic 
neurites of AD brain [7, 8, 19, 22, 89]. In addition, we have 
shown here and in a previous study [121] that BACE1 co-
localizes with synaptophysin, but not MAP2, in dystrophic 
neurites surrounding plaques in human AD brain in a pat-
tern that is similar to that seen in 5XFAD brain. We con-
clude that 5XFAD mice recapitulate the pattern of BACE1 
accumulation in plaque-associated dystrophies observed 
in human AD. Thus, investigation of BACE1 elevation in 
5XFAD mice should provide valuable insight into the for-
mation and progression of amyloid plaques in AD.
We observed different subtypes of dystrophic neurites 
in the 5XFAD brain, which we termed Type I and Type II, 
that were distinguishable based on the size, degree of elec-
tron density, and multi-lamellar nature of membrane-bound 
(autophagic intermediate-like) structures within a given 
neurite. Generally, Type I dystrophic neurites were less 
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electron dense and contained smaller membraneous struc-
tures, while Type II dystrophies were more electron dense 
and contained larger, multi-lamellar structures. BACE1 
immuno-EM signal was highest in Type I dystrophies 
that contain smaller, less electron-dense vesicles. Type II 
dystrophic neurites, which exhibit large multi-lamellar 
autophagosomes, had much lower BACE1 immunogold 
labeling. Although the identity of BACE1-positive vesicles 
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in Type I dystrophies is unknown, we suspect they are 
endosomes based on the high degree of co-localization of 
BACE1 and transferrin receptor by immunofluorescence 
confocal microscopy. Poor co-localization of BACE1 with 
LAMP1 and LC3B allows us to exclude lysosomes and 
autophagosomes as primary organelles of BACE1 accumu-
lation, respectively. These data concur with our immuno-
EM results showing lack of BACE1 localization to multi-
lamellar autophagosomes. We speculate that Type I and 
Type II dystrophies represent a continuum of the disease 
process, whereby Type I represents an earlier stage of dis-
ease. This notion is supported by EM studies that character-
ize dystrophic neurites at different stages of degeneration in 
AD mouse models [1, 23] and human AD [109], the latter 
in which two types of dystrophies were described having 
either large globoid APP and chromogranin-immunoposi-
tive or tau-immunopositive morphologies. The former may 
represent an early stage of dystrophy, while the latter are 
neurofibrillary tangle (NFT)-containing structures at a late 
stage of degeneration. 5XFAD mice do not have NFTs and 
therefore lack this late-stage dystrophic neurite. However, 
5XFAD dystrophies may be related to early-stage globoid 
APP and chromogranin-positive AD dystrophic neurites, 
thus fitting with the general consensus that APP transgenic 
mice model an earlier phase of AD.
Roles of autophagy, lysosomes, and microtubule transport 
in BACE1 accumulation in AD
Dystrophic neurites are positive for markers of autophagy 
[14, 72] and at the ultrastructural level contain multi-
lamellar autophagosomes [8, 23, 45, 71, 72, 89, 100, 119] 
observed in 5XFAD Type II dystrophies. Additionally, 
5XFAD hippocampi had an elevated LC3B-II:LC3B-I 
ratio, indicating increased autophagy consistent with accu-
mulation of autophagosomes by EM and concurring with 
elevated LC3B-II:LC3B-I ratio in another APP transgenic 
[89]. The increased markers of autophagy correlate with 
elevated BACE1 levels in 5XFAD hippocampus, although 
both BACE1 immuno-EM and BACE1-LC3B co-localiza-
tion by confocal microscopy suggest that BACE1 does not 
accumulate in autophagosomes.
BACE1 accumulation in endosomes of 5XFAD presyn-
aptic dystrophic neurites suggests three potential mecha-
nisms: (1) BACE1 is degraded by autophagy, but an ear-
lier step of the autophagic pathway is impaired (e.g., 
fusion of endosomes with autophagosomes); (2) BACE1 is 
degraded by lysosomes, but an earlier step of the lysoso-
mal pathway is impaired (e.g., lysosomal acidification or 
maturation); (3) BACE1 clearance requires microtubule 
transport, but microtubules are dysfunctional (e.g., fail-
ure of BACE1 transport back to the soma). To gain ini-
tial insights into these mechanisms, we investigated the 
roles of autophagy and the lysosomal pathway in BACE1 
clearance in cultured primary neurons. Previous studies 
reported that axonal dystrophy could result from inhibi-
tion of lysosomal proteolysis [4, 5, 58, 59]. Treatment of 
primary neurons with the lysosomal protease inhibitor 
leupeptin resulted in elevated BACE1 levels and a small 
increase in the LC3B-II:LC3B-I ratio, the latter of which 
indicates reduced autophagosome clearance. These results 
support earlier work suggesting that BACE1 is degraded 
in lysosomes [51, 103]. In contrast, inducing autophagy in 
primary neurons with trehalose resulted in a large increase 
in LC3B-II:LC3B-I ratio, but had no effect on BACE1 
level. If autophagy cleared BACE1 in neurons, then 
BACE1 should significantly decrease following trehalose 
treatment. Hypothetically, BACE1 could be an autophagy 
substrate under other conditions of autophagy induction; 
however, we find this possibility unlikely. Hence, BACE1 
does not appear to be a target of autophagy, at least in pri-
mary neurons. Rather, our data indicate that BACE1 accu-
mulation may result from impaired lysosomal degradation 
of BACE1.
Fig. 10  BACE1 is degraded by lysosomes, but not by autophagy. 
a–f The autophagy marker LC3B-II is elevated in the 5XFAD brain. 
a Homogenates of individual hippocampi from ~6-month-old 5XFAD 
(+) and non-transgenic (−) mice were analyzed by immunoblot for 
BACE1 and LC3B. Note the increased intensity of the LC3B-II band 
in 5XFAD compared to non-transgenic hippocampi. β-Tubulin was 
used as a loading control. b Densitometric analysis of LC3B-II signal 
intensity in a, normalized to that of LC3B-I, shows ~700 % increase 
in the LC3B-II:LC3B-I ratio in 5XFAD hippocampi compared to 
non-transgenic controls. c Densitometric analysis of BACE1 signal 
intensity in a, normalized to that of β-tubulin, shows ~50 % increase 
in BACE1 levels in 5XFAD hippocampi compared to non-transgenic 
controls (**p < 0.01, t test, n = 5 for b, c). d–f Representative images 
of brain sections from ~6-month-old 5XFAD mice co-stained with 
BACE1 (red) and LC3B (green) antibodies and imaged by laser 
scanning confocal microscopy. BACE1 and LC3B immunoreactivi-
ties largely occur in non-overlapping patterns in dystrophic neurites 
surrounding amyloid plaques (white asterisks). Note that dystrophic 
neurites immunopositive for LC3B typically display minimal BACE1 
immunoreactivity, and vice versa. g Primary cortical neuron cultures 
from wild-type E15.5–16.5 mouse embryos were treated with either 
vehicle, 20 μM leupeptin (a lysosomal protease inhibitor), 150 mM 
trehalose (an inducer of autophagy), or leupeptin plus trehalose for 
24 or 48 h, and then analyzed for BACE1, LC3B-I and LC3B-II lev-
els by immunoblot. Ponceau staining was used as a loading control. 
h Densitometric analysis of the ratio of LC3B-II to LC3B-I levels in 
g shows a dramatic increase in LC3B-II:LC3B-I with trehalose and 
leupeptin plus trehalose treatment, demonstrating that trehalose is a 
strong inducer of autophagy in neurons. In contrast, leupeptin alone 
causes only a relatively modest elevation of neuronal LC3B-II:LC3B-
I ratio. i Densitometric analysis of BACE1 levels in g, normalized to 
ponceau, shows a marked increase of BACE1 levels with leupeptin 
treatment in neurons, while trehalose does not decrease BACE1 lev-
els. These results suggest that BACE1 is not cleared by autophagy 
but instead is likely degraded in the lysosomal pathway in neurons, at 
least in culture (*p < 0.05, **p < 0.01, ***p < 0.001 ANOVA, n = 3 
for h, i). Scale bar d–f, 20 μm
◂
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Taken together, our in vitro and in vivo results indicate 
that BACE1 accumulates in endosomes within presynaptic 
dystrophic neurites surrounding plaques, suggesting that 
BACE1 degradation could be reduced due to decreased 
BACE1 flux through the endosomal–lysosomal pathway. 
Although the 5XFAD brain exhibits robust accumulation of 
autophagosomes and increased LC3B-II, autophagy does 
not appear to be directly involved in BACE1 clearance. The 
evidence for this is the following: (1) BACE1 co-localizes 
with synaptophysin and transferrin receptor but not MAP2, 
LAMP1 or LC3B, indicating that BACE1 accumulates in 
presynaptic endosomes but not lysosomes or autophago-
somes; (2) BACE1 immunogold labels small electron trans-
lucent vesicles, not large electron-dense multi-lamellar 
autophagosomes; and (3) lysosomal protease inhibition ele-
vates neuronal BACE1, but autophagy induction does not 
reduce BACE1.
The reason for reduced endosomal–lysosomal BACE1 
flux is unclear, although aberrant accumulation of α- and 
β-tubulin in dystrophic neurites implies that dysfunctional 
microtubules could play a role. Lysosome maturation 
requires vesicles laden with lysosomal proteases that are 
derived from the Golgi apparatus in the soma. If micro-
tubule-based axon transport is impaired by amyloid, defi-
cient protease levels in presynaptic lysosomes may ensue 
resulting in reduced protein degradation. Although specu-
lative, this model would provide a plausible mechanism 
for increased BACE1 levels in dystrophies near plaques. 
Similarly, organelle accumulation in dystrophic neurites 
has been postulated to arise from impaired axon transport 
[70]. In addition, AD brains show reduced levels of dynein 
and kinesin, molecular motors critical for axoplasmic trans-
port [69]. Loss of retrograde transport in dystrophies could 
also contribute to accumulation of autophagosomes and 
BACE1-positive vesicles in axon terminals, causing neu-
rites to swell as vesicles and mitochondria amass within. 
The molecular nature of the plaque-related toxic agent 
and mechanism responsible for neuritic dystrophy and 
BACE1 accumulation are unclear, but likely involve Aβ, 
given the intimate association of dystrophies with plaques. 
Alternatively, dystrophic neurite formation may involve 
reticulon/Nogo proteins (reviewed in [81]), since transgenic 
mice that overexpress reticulon-3 form plaque-independent 
neuritic dystrophies [38, 94, 95]. Future work should eluci-
date mechanisms of dystrophic neurite pathogenesis.
In summary, our study provides the first conclusive 
evidence, as shown by electron microscopy, that BACE1 
resides predominantly within normal and dystrophic pre-
synaptic terminals in wild-type and AD mouse model brain, 
consistent with our immunofluorescence microscopy of 
human AD. Presynaptic BACE1 localization suggests that 
BACE1 substrate processing has important consequences 
for axon terminal function. BACE1 and APP accumulate 
in presynaptic dystrophies surrounding amyloid plaques, 
implying a feed-forward mechanism of Aβ generation that 
may exacerbate AD pathogenesis. Deficient lysosomal 
degradation, but not impaired autophagy, of BACE1 could 
cause BACE1 accumulation in presynaptic endosomes. 
Although the molecular mechanism of BACE1 elevation 
around plaques is enigmatic, evidence of abnormal tubu-
lin accumulation implies dysfunctional microtubule-based 
transport. Other mechanisms are possible, such as impaired 
lysosomal acidification or enzymatic activity [58]. Future 
studies to elucidate mechanisms of BACE1 elevation in 
dystrophies may provide insights into potential therapeutic 
avenues to reduce BACE1 levels and ameliorate AD.
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